Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

Shots:

• GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21
• The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches
• The agreement includes the global rights to three established brands (Zinnat, Zinacef, and Fortum) in 100+ markets. Additionally, Sandoz plans to expand its integrated manufacturing site in Kundl with the manufacturing of Zinnat

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Law.com